牛牛AI助理已提取核心訊息
FOXO Technologies Inc. reported financial results for the quarter ended September 30, 2023, with a net loss of $3.66 million, a significant improvement from the $41.03 million loss in the same period last year. The company's total revenue decreased by 29% year-on-year to $10 thousand, primarily due to reduced life insurance commissions as the company ceased placing policies from its legacy agency business. Research and development expenses decreased by 49% to $283 thousand, reflecting lower employee-related expenses and professional services. The company also reported a non-operating expense decrease of 153%, mainly due to changes in the fair value of convertible debentures, warrant liability, and forward purchase derivatives. FOXO Technologies continues to focus on commercializing epigenetic biomarker technology and has launched Bioinformatics Services. However, the...Show More
FOXO Technologies Inc. reported financial results for the quarter ended September 30, 2023, with a net loss of $3.66 million, a significant improvement from the $41.03 million loss in the same period last year. The company's total revenue decreased by 29% year-on-year to $10 thousand, primarily due to reduced life insurance commissions as the company ceased placing policies from its legacy agency business. Research and development expenses decreased by 49% to $283 thousand, reflecting lower employee-related expenses and professional services. The company also reported a non-operating expense decrease of 153%, mainly due to changes in the fair value of convertible debentures, warrant liability, and forward purchase derivatives. FOXO Technologies continues to focus on commercializing epigenetic biomarker technology and has launched Bioinformatics Services. However, the company faces challenges, including a history of losses, the need for additional capital, and maintaining compliance with NYSE American listing standards. As of September 30, 2023, FOXO Technologies had cash and cash equivalents of $42 thousand, and the company's accumulated deficit stood at $172.29 million. The company's future plans include pursuing additional funding and focusing on research and development to grow its business.
FOXO Technologies Inc.公佈了截至2023年9月30日的季度財務業績，淨虧損爲366萬美元，比去年同期的4,103萬美元虧損有了顯著改善。該公司的總收入同比下降29％，至1萬美元，這主要是由於公司停止從其傳統代理業務中投保人壽保險佣金減少。研發費用下降了49％，至28.3萬美元，這反映了與員工相關的費用和專業服務的減少。該公司還報告稱，營業外支出下降了153％，這主要是由於可轉換債券、認股權證負債和遠期購買衍生品的公允價值的變化。FOXO Technologies繼續專注於表觀遺傳生物標誌物技術的商業化，並推出了生物信息學服務。但是，該公司面臨着挑戰，包括虧損歷史、對額外資本的需求以及維持對紐約證券交易所美國上市標準的遵守。截至2023年9月30日，FOXO Technologies的現金及現金等價物爲42,000美元，該公司的累計赤字爲1.7229億美元。該公司的未來計劃包括尋求額外資金和專注於研發以發展其業務。
FOXO Technologies Inc.公佈了截至2023年9月30日的季度財務業績，淨虧損爲366萬美元，比去年同期的4,103萬美元虧損有了顯著改善。該公司的總收入同比下降29％，至1萬美元，這主要是由於公司停止從其傳統代理業務中投保人壽保險佣金減少。研發費用下降了49％，至28.3萬美元，這反映了與員工相關的費用和專業服務的減少。該公司還報告稱，營業外支出下降了153％，這主要是由於可轉換債券、認股權證負債和遠期購買衍生品的公允價值的變化。FOXO Technologies繼續專注於表觀遺傳生物標誌物技術的商業化，並推出了生物信息學服務。但是，該公司面臨着挑戰，包括虧損歷史、對額外資本的需求以及維持對紐約證券交易所美國上市標準的遵守。截至2023年9月30日，FOXO Technologies的現金及現金等價物爲42,000美元，該公司的累計赤字爲1.7229億美元。該公司的未來計劃包括尋求額外資金和專注於研發以發展其業務。
有用
沒用
